Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools?
BACKGROUND
Classically, the first step in the clinical development of drugs in oncology involves assessments of dose limiting toxicity (DLT) and maximum tolerated dose (MTD). New paradigms are needed for antiangiogenic drugs and vascular disrupting agents (VDAs) as they are active at doses well below the MTD and as single agents their use might not translate into anti-tumour efficacy. MRI is able to assess the antivascular effects of antivascular drugs via changes in functional kinetic parameters; however, the usefulness of MRI in decision making has been questioned by many.


OBJECTIVE
Our aim is to review the experience of using dynamic contrast-enhanced MRI (DCE-MRI) in early clinical development of vascular directed anticancer therapies over the last decade. Thirty-nine phase I and II studies including data on more than 700 patients have been published as abstracts and/or papers, documenting DCE-MRI changes after the administration of antiangiogenic drugs and VDAs.


CONCLUSIONS
Perfusion MRI is helpful in assessing whether mechanistic goals are achieved, in assisting dose selection for phase II studies, in selecting subpopulations enriched for response and in predicting patient benefit. Imaging tools are increasingly available. Future challenges for imaging include correlation with clinical measures of efficacy and determining relationships with blood and serum biomarkers.
Zweifel
Martin
M
Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, UK.
Padhani
Anwar R
AR
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D001808:Blood Vessels / Q000187:drug effects* / Q000503:physiopathology; D003287:Contrast Media; D003657:Decision Making; D055808:Drug Discovery / Q000379:methods*; D006801:Humans; D018810:Magnetic Resonance Angiography / Q000379:methods*; D009369:Neoplasms / Q000098:blood supply / Q000175:diagnosis / Q000188:drug therapy
D020533:Angiogenesis Inhibitors; D003287:Contrast Media
J Clin Oncol. 2006 Feb 10;24(5):769-77
16391297
Eur J Cancer. 2005 Jun;41(9):1291-9
15939265
Ann Oncol. 2009 Apr;20(4):741-5
19190075
J Clin Oncol. 2003 Aug 1;21(15):2831-42
12807936
J Clin Oncol. 2002 Sep 15;20(18):3826-40
12228202
Clin Cancer Res. 2004 Jun 1;10(11):3650-7
15173071
Br J Cancer. 2005 May 9;92(9):1599-610
15870830
Clin Cancer Res. 2005 Feb 15;11(4):1527-33
15746056
J Clin Oncol. 2002 Sep 15;20(18):3804-14
12228200
Cancer Cell. 2009 Mar 3;15(3):167-70
19249675
Radiology. 2007 Sep;244(3):727-35
17709827
Top Magn Reson Imaging. 2004 Feb;15(1):41-57
15057172
Science. 2006 Sep 22;313(5794):1785-7
16990548
Br J Cancer. 2005 Oct 17;93(8):876-83
16222321
J Clin Oncol. 2002 Sep 15;20(18):3772-84
12228197
J Clin Oncol. 2003 Dec 1;21(23):4428-38
14645433
J Clin Oncol. 2003 Aug 1;21(15):2807-9
12807933
Int J Oncol. 2007 Feb;30(2):453-60
17203228
J Magn Reson Imaging. 2007 Apr;25(4):796-805
17347990
Cancer Res. 2002 Jun 15;62(12):3408-16
12067983
Invest New Drugs. 2004 Nov;22(4):459-66
15292716
Nat Med. 2001 Sep;7(9):987-9
11533692
J Clin Oncol. 2009 May 20;27(15):2542-52
19332720
Eur Radiol. 2004 Feb;14(2):309-17
14531000
Invest New Drugs. 2008 Apr;26(2):159-67
18219445
Cancer Cell. 2007 Jan;11(1):83-95
17222792
J Clin Oncol. 2007 May 1;25(13):1760-4
17470866
J Clin Oncol. 2003 Aug 1;21(15):2815-22
12807934
Cancer Res. 2005 Aug 15;65(16):7041-4
16103049
J Natl Cancer Inst. 2002 Oct 2;94(19):1484-93
12359857
J Clin Oncol. 2003 Jan 15;21(2):223-31
12525513
J Magn Reson Imaging. 1997 Jan-Feb;7(1):91-101
9039598
J Ultrasound Med. 2007 Jun;26(6):749-56
17526606
Neoplasia. 2007 Jul;9(7):546-55
17710157
J Clin Oncol. 2005 Aug 20;23(24):5464-73
16027440
Nat Clin Pract Oncol. 2008 Apr;5(4):220-33
18301415
Magn Reson Med. 2002 Mar;47(3):601-6
11870848
Cancer Res. 2009 Jul 1;69(13):5296-300
19549889
J Clin Oncol. 2008 Oct 1;26(28):4572-8
18824708
Clin Cancer Res. 2009 Nov 1;15(21):6674-82
19861458
J Clin Oncol. 2007 Jun 10;25(17):2369-76
17557949
Curr Mol Med. 2003 Dec;3(8):673-91
14682490
Cancer Biol Ther. 2008 Apr;7(4):496-501
18219225
J Clin Oncol. 2009 Jun 20;27(18):3027-35
19470923
Physiol Chem Phys Med NMR. 1984;16(2):167-72
6505043
J Clin Oncol. 2003 Nov 1;21(21):3955-64
14517187
Clin Cancer Res. 2005 Nov 1;11(21):7938-44
16278419
Nat Med. 2004 Feb;10(2):145-7
14745444
Magn Reson Med. 2002 Feb;47(2):420-4
11810690
Clin Cancer Res. 2009 Jul 1;15(13):4484-92
19549771
Clin Cancer Res. 2009 May 15;15(10):3583-90
19417018
J Clin Oncol. 2005 Feb 10;23(5):973-81
15466784
Clin Cancer Res. 2006 Mar 15;12(6):1776-84
16551862
Acad Radiol. 2008 Oct;15(10):1246-54
18790395
Magn Reson Med. 2000 Oct;44(4):563-74
11025512
J Magn Reson Imaging. 2004 Jul;20(1):122-8
15221817
Phys Med Biol. 2007 Jan 7;52(1):75-89
17183129
J Clin Oncol. 2005 Jun 20;23(18):4162-71
15867205
J Magn Reson Imaging. 1999 Sep;10(3):223-32
10508281
Radiology. 2009 May;251(2):317-35
19401568
Br J Cancer. 2003 Jul 21;89(2):262-7
12865914
Neurosurgery. 2006 Apr;58(4):640-6; discussion 640-6
16575327
Br J Cancer. 2005 Oct 31;93(9):979-85
16234826